???????Eckert & Ziegler: Dividend Proposal EUR 0.45 per Share. Profit Increase in 2020. Positive Outlook for 2021.
March 25, 2021 at 02:56 pm EDT
Share
DGAP-Ad-hoc: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Dividend/Forecast
???????Eckert & Ziegler: Dividend Proposal EUR 0.45 per Share. Profit Increase in 2020. Positive Outlook for 2021.
25-March-2021 / 19:52 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Berlin, 25 March 2021 - Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) achieved sales of EUR 176.1 million (previous year EUR 178.5 million) and a net profit of EUR 22.9 million (previous year EUR 22.0 million) in the 2020 financial year. Earnings per share amounted to EUR 1.11. Executive Board and Supervisory Board today resolved to propose to the Annual General Meeting the payment of a split-adjusted dividend in the amount of EUR 0.45 (previous year: EUR 0.42) per share entitled to dividend.
For the current financial year 2021, the Executive Board expects revenue to remain at the previous year's level, net profit of around EUR 29 million and EPS of around EUR 1.40. The forecast is based on a weighted average exchange rate of USD 1.15 per euro and the assumption that no shutdowns of significant production sites or other disruptions will be ordered due to the COVID19 pandemic.
Information and Explanation of the Issuer to this News:
The income statement, balance sheet and cash flow statement for the past financial year can be found here. The complete, audited annual financial statements 2020 will be published on 16 April 2021.
25-March-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone:
+49 30 941084-138
Fax:
+49 30 941084-112
E-mail:
karolin.riehle@ezag.de
Internet:
www.ezag.de
ISIN:
DE0005659700
WKN:
565970
Indices:
SDAX
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
Eckert & Ziegler SE is a Germany-based Company, which is a provider of isotope technology for medical, scientific and industrial use with focus on cancer therapy, industrial radiometry and nuclear-medical imaging. The Company operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
ECKERT & ZIEGLER SE 
